BACKGROUND: 5-Hydroxytryptamine type 3 (5-HT 3 ) receptors are excitatory ion channels belonging to the cys-loop family of ligand-gated ion channels. They are involved in nausea and vomiting and their antagonists are used clinically as antiemetic drugs. We previously reported the development of a novel pyrrole analog of etomidate, (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate), which retains etomidate's desirable anesthetic and hemodynamic properties, but lacks its potent inhibitory effect on adrenocorticotropic hormone-stimulated steroid synthesis. Also in contrast to etomidate, carboetomidate potently inhibits nicotinic acetylcholine receptors. Because nicotinic acetylcholine and 5-HT 3 receptors are highly homologous, we hypothesized that carboetomidate might also potently inhibit 5-HT 3 receptors with potentially important implications for the drug's emetogenic activity. In the current studies, we investigated and compared modulation of 5-HT 3A receptors by carboetomidate and etomidate. METHODS: 5-HT 3 receptors were heterologously expressed in human embryonic kidney cells. Drugs were applied with a multichannel superfusion pipette coupled to piezoelectric elements, and currents were recorded from cells in either the whole-cell or excised outside-out patch configuration of patch-clamp recordings. RESULTS: Carboetomidate and etomidate inhibited integrated 5-HT 3A receptor-mediated currents with respective half-inhibitory concentrations of 1.9 μM (95% confidence interval [CI] = 1.4-2.7 μM) and 25 μM (95% CI = 17-37 μM). These values may be compared with respective hypnotic concentrations of 5.4 and 2.3 µM. This inhibition reflected hypnotic effects on peak current amplitudes and desensitization rates. Half-inhibitory concentrations for reducing peak current amplitudes were 34 μM (95% CI = 24-48 µM) for carboetomidate and 171 μM (95% CI = 128-228 µM) for etomidate. Half-inhibitory concentrations for reducing the desensitization time constant were 3.5 μM (95% CI = 2.4-5.1 µM) for carboetomidate and 36 μM (95% CI = 21-59 µM) for etomidate. CONCLUSIONS: In contrast to etomidate, carboetomidate inhibits 5-HT 3A receptor-mediated currents at hypnotic concentrations. This inhibition is primarily the result of enhancing the rate of desensitization. Because carboetomidate potently inhibits 5-HT 3A receptors, it may be less emetogenic than etomidate. (Anesth Analg 2013;116:573-9)
aNesthesia & aNalgesia
Carboetomidate Inhibits 5-HT 3A Receptors action on GABA A receptors and ability to produce hypnosis, but lacks its potent inhibitory effect on adrenocorticotropic hormone-stimulated steroid synthesis and enhancing effect on proinflammatory cytokine production in a model of sepsis. [7] [8] [9] Our subsequent studies showed additional pharmacologic differences between the 2 drugs as carboetomidate inhibits neuronal nicotinic acetylcholine receptors at clinically relevant (i.e., hypnotic) concentrations whereas etomidate does not. 10 Because nicotinic acetylcholine and 5-HT 3 receptors are structurally and functionally highly homologous, we hypothesized that carboetomidate would also inhibit 5-HT 3 receptors at hypnotic concentrations. Such inhibition of 5-HT 3 receptors could have important clinical implications if it leads to a reduction in the emetogenic potential of carboetomidate relative to that of etomidate.
To test our hypothesis that carboetomidate inhibits 5-HT 3 receptors at hypnotic concentrations, we defined the effects of carboetomidate on 5-HT 3A receptors using wholecell and excised outside-out configurations of the patchclamp technique. For comparison, we also defined the effects of etomidate on this receptor. Our studies showed that whereas both hypnotics inhibit 5-HT 3A receptor function, carboetomidate is an order of magnitude more potent than etomidate and produces significant receptor inhibition at hypnotic concentrations.
METHODS
IRB approval for these studies was not sought because neither animals nor humans were used.
Drugs and Solutions
5-HT was obtained from Sigma-Aldrich (St. Louis, MO). 5-HT solutions were freshly prepared daily in bath solution. Etomidate was purchased from Bachem Americas (Torrance, CA) and carboetomidate was custom synthesized (>95% purity) by Aberjona Laboratories (Beverly, MA) using our previously described method. One-molar stocks of both etomidate and carboetomidate were prepared in dimethyl sulfoxide (DMSO) and stored at −20°C in glass vials. Working solutions of both drugs were prepared fresh daily from DMSO stock solutions. For carboetomidate experiments, the highest final concentration of DMSO was 0.004%, which had no effect on 5-HT 3A currents. For etomidate experiments, the highest final concentration of DMSO was 0.1%, which inhibited 5-HT 3A peak current amplitudes by approximately 10%. Because this DMSO concentration was achieved only in experiments using 1 mM etomidate, no attempt was made to correct for this additional modest level of inhibition.
Cell Culture and Preparation of Inducible Stable Cell Line Expressing 5-HT 3A Receptors
Human 5-HT 3A cDNA (accession no. NM_000869) was subcloned into tetracycline-regulated expression vector pCDNA4/TO (Life Technologies, Grand Island, NY) using the BamH I and NotI sites. Previously generated human embryonic kidney 293 cells stably expressing tetracycline repressor protein (HEK293-TetR) cells 11 were grown in Dulbecco's modified Eagle medium/F12 (Life Technologies) supplemented with 10% fetal bovine serum (heat-inactivated), 100 U/mL penicillin/streptomycin, and 5 μg/mL blasticidin, in a 5% CO 2 incubator at 37°C. HEK293-TetR cells were seeded in a 25-cm 2 cell culture flask 24 hours before transfection and maintained at 37°C until they were approximately 90% confluent. Cells were then transfected with 15 μg of 5-HT 3A -pCDNA4/TO plasmid DNA using Lipofectamine (Life Technologies) according to the manufacturer's recommendations. Twenty-four hours posttransfection, Zeocin (250 μg/mL; Life Technologies) was added to the culture medium and cells were grown for another 2 weeks to obtain Zeocin-resistant cells. The Zeocin-resistant cells were subjected to single-cell sorting using the analytic 7-laser LSR flow cytometer (BD Biosciences, Durham, NC) at the Massachusetts General Hospital research flow cytometry core facility to sort single cell per well in a 96-well plate. Colonies from single cells were allowed to grow to confluence before testing them for 5-HT 3A receptor expression. After 24-hour induction with tetracycline, single clones expressing high levels of 5-HT 3A channels were identified with whole-cell patch-clamp electrophysiology.
Membrane Isolation and Western Blotting
HEK293 cells expressing 5-HT 3A channels (24 hours postinduction with tetracycline) were harvested by scraping and were washed twice in ice-cold phosphatebuffered saline (PBS). Crude membranes were isolated from harvested cells and Western blot was performed as previously described. 12 Blots were air-dried overnight and then blocked in PBS containing 10% nonfat milk and 0.05% Tween 20 (blocking buffer) for 1 hour at room temperature with shaking. Blots were then incubated with 1 μg/mL anti-5-HT 3A antibody (goat polyclonal immunoglobulin G; Tocris Bioscience, Minneapolis, MN) in the blotting buffer overnight at 4°C. After 3 washes with blocking buffer, blots were incubated for 1 hour with horseradish peroxidaseconjugated mouse anti-goat antibody, followed by extensive washes in PBS. Labeled proteins were detected by enhanced chemiluminescence (Fig. 1 ). The predicted molecular weight of mature 5-HT 3A protein is 52.8 kDa. In Western blot analysis, anti-5-HT 3A antibody specifically recognized an approximately 50-kDa protein band in tetracycline-induced 5-HT 3A -HEK293 cells, but not in control uninduced cells ( Fig. 1 ). In the tetracycline-induced lane, we also detected bands at approximately 100, 200, and 250 kDa, which may represent aggregates of channel protein. Based on the resolving power of our gel, our inducible cell line appears to express the full-length 5-HT 3A protein.
Electrophysiology
Whole-cell or excised outside-out configuration of the patchclamp technique was used to record currents from HEK293 cells expressing 5-HT 3A receptors. Cells were seeded on a glass coverslip and channel expression was induced with tetracycline (2 μg/mL) 24 to 36 hours before recordings. All experiments were performed at room temperature (20°C-22°C). The recording chamber was continuously perfused with the bath solution: (in mM) 150 NaCl, 0.5 CaCl 2 , and 10 HEPES, pH 7.4 (pH adjusted with NaOH). The electrode solution contained (in mM) 134 KCl, 5 EGTA, 1 MgCl 2 , and 10 HEPES, pH 7.4 (pH adjusted with KOH). The open pipette resistances ranged from 2 to 4 MΩ for whole-cell recordings and 4 to 8 MΩ for outside-out patches. Cells and patches were voltage clamped at −70 mV using the patch-clamp amplifier (Axopatch 200B; Molecular Devices Corp., Sunnyvale, CA). Whole-cell membrane capacitance and series resistance were compensated electronically by >85% with a lag of 10 milliseconds. Series resistance ranged from 1 to 5 MΩ and cell capacitances from 3.5 to 10 pF. 5-HT 3A receptors were activated with 5-HT delivered via a multichannel superfusion pipette coupled to piezoelectric elements that switched superfusion solution in <1 millisecond. Currents were digitized at 2 kHz and filtered at 1 kHz, and pCLAMP version 8.1 (Molecular Devices Corp.) was used for offline analysis. Five to 10 pulses of 5-HT were applied 120 seconds apart until the peak currents stabilized before applying hypnotic drugs. During whole-cell recordings, the hypnotics were applied in equilibrium, by preincubating the cells for 5 minutes in bath solution containing hypnotic before its coapplication with 100 μM 5-HT.
Data Analysis and Statistics

5-HT 3A Receptor Inhibition by Hypnotics and Recovery from Inhibition
Control traces of nondesensitizing 5-HT 3A currents were obtained by applying a 30-second pulse of 1 μM 5-HT. Hypnotic effects were assessed by sequential application of agonist alone (for 10-15 seconds until peak amplitudes were reached), followed by agonist plus hypnotic for 10 seconds, and then returned to agonist alone (10 seconds). To evaluate inhibition, percent changes in maximum peak current amplitude obtained during the first agonist alone pulse and minimum amplitude obtained during the agonist and hypnotic pulse from the same trace were calculated. For assessing recovery from inhibition, the percent change in peak current amplitudes between the first and second 1-μM 5-HT pulses were calculated.
Determination of Half-Inhibitory Hypnotic Concentrations for Reducing Integrated Currents and Peak Current Amplitudes
Control currents were obtained by perfusing whole cells with bath solution containing 100 µM 5-HT for 30 seconds. After a 2-minute recovery period, test currents were obtained by perfusing the same cell first with bath solution containing the desired hypnotic (for 5 minutes) and then with bath solution containing both hypnotic and 100 µM 5-HT for 30 seconds. From each recorded current trace, the integrated current (i.e., the area under the curve) and peak current amplitude were calculated. To account for variable receptor expression in cells, integrated currents and peak current amplitudes obtained in the presence of hypnotic were normalized to the control values obtained in the absence of hypnotic in the same cell. Hypnotic concentration-normalized response curves were fit to a Hill equation in the following form:
where I norm is the normalized integrated current (or peak current) obtained in the presence of hypnotic and the IC 50 is the hypnotic concentration that reduces the integrated current (or peak current) by half.
Determination of Time Constants for Desensitization and Deactivation
Decay phase of currents was fitted with exponential functions using the Levenberg-Marquardt algorithm with least-square minimization to determine time constants for deactivation and desensitization. The number of exponentials that best fit the decay of currents was determined using an F test. Most decay components were best fit by 2 exponentials; however, some were fitted by >2 exponentials. To allow for comparisons, a weighted time constant Στ(A/ΣA n ) was determined. Current traces were analyzed using Clampfit version 9.0 (Molecular Devices Corp.).
All statistical analyses (curve fitting of dose-response relationships, 95% confidence interval [CI] determinations, and Student t tests using Welch's method) were performed using GraphPad Prism version 5 software (GraphPad Software, Inc., San Diego, CA). For each experiment, a sample size was chosen based on an assessment of the magnitude and variability of the hypnotic effect observed in pilot experiments. Because the differences between carboetomidate and etomidate in measured integrated areas, peak amplitudes, and desensitization rates were large and consistent, we anticipated that statistical significance could be achieved with a relatively small sample size (i.e., n = 3-5 cells). Hypnotic effects on deactivation rates measured in patches were smaller and less consistent. Therefore, a larger sample size was used (n = 7 patches). All data are expressed as mean ± SEM.
RESULTS
Carboetomidate Inhibits 5-HT 3A Receptors at Hypnotic Concentrations Whereas Etomidate Does Not
As an initial assessment of the effects of carboetomidate and etomidate on 5-HT 3A receptor function, we activated 5-HT 3A receptors with 1 µM 5-HT (a low agonist concentration that submaximally activates receptors and induces little receptor desensitization) and then coapplied either carboetomidate 
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Carboetomidate Inhibits 5-HT 3A Receptors or etomidate (10 µM). In Figure 2A , the left panel shows a representative control current trace obtained on application of 1 µM 5-HT without hypnotic, whereas the middle and right panels show the rapid but only partially reversible inhibition produced by carboetomidate and etomidate when coapplied with 1 µM 5-HT for 10 seconds during the 30-second 1-µM 5-HT pulse. In these experiments, inhibition was greater and recovery was less with coapplication of carboetomidate than with etomidate. Figure 2B shows the results of multiple experiments (n = 3-5) using this protocol and demonstrates that the differences between these 2 agents were highly statistically significant; inhibition was greater (85.5% ± 0.2% vs 33% ± 2%, P < 0.0001; left panel) and recovery less (57% ± 4% vs 87.1% ± 0.9%, P < 0.0001; right panel) with carboetomidate than with etomidate. Figure 3A shows representative current traces obtained when 5-HT 3A receptors were pre-equilibrated for 5 minutes with either carboetomidate (left panel) or etomidate (right panel) and then activated for 30 seconds with 100 µM 5-HT, a concentration that induces maximal receptor activation followed by desensitization. These traces show that both hypnotics inhibit 5-HT 3A receptor-mediated currents. To quantify carboetomidate and etomidate potencies, IC 50 values for inhibiting integrated currents were derived from studies using a range of hypnotic concentrations (Fig.  3B, left panel) . These studies showed that both hypnotics reduced integrated currents in a concentration-dependent manner. However, carboetomidate inhibited integrated currents significantly more potently than etomidate with respective IC 50 values of 1.9 μM (95% CI = 1.4-2.7 μM) and 25 μM (95% CI = 17-37 μM). These IC 50 values are 35% and 1100% of the hypnotic 50% effective concentrations for carboetomidate and etomidate, respectively.
Because hypnotic effects on integrated currents clearly reflected the combined actions on peak current amplitudes and desensitization rates, we also individually characterized these actions. The middle and right panels in Figure 3B show that both carboetomidate and etomidate produce concentration-dependent reductions in both peak currents and weighted time constants for desensitization. In both cases, carboetomidate acted more potently than etomidate. The calculated IC 50 values for peak current inhibition were 34 μM (95% CI = 24-48 µM) for carboetomidate and 171 μM (95% CI = 128-228 µM) for etomidate. The calculated IC 50 values for reducing the desensitization time constant were 3.5 μM (95% CI = 2.4-5.1 µM) for carboetomidate and 36 μM (95% CI = 21-59 µM) for etomidate. 
Carboetomidate Accelerates 5-HT 3A Receptor Deactivation
We further investigated carboetomidate's effect on the 5-HT 3A receptor after very brief (4-millisecond) 5-HT exposure as might be encountered at a synapse. To achieve such a rapid change in agonist concentration, we used excised outside-out patches expressing 5-HT 3A receptors rather than whole cells. Figure 4A shows representative normalized current traces demonstrating the effects of carboetomidate on the rate of channel closure after a brief agonist pulse (i.e., deactivation) using such patches. In control traces (i.e., no carboetomidate), the deactivation time constant was 460 ± 130 milliseconds (n = 7). Carboetomidate significantly reduced the time constant (increased the deactivation rate) to 110 ± 25 milliseconds ( Fig. 4B ; n = 5; Student t test using Welch's method, P = 0.033).
DISCUSSION
Our studies show that carboetomidate and etomidate inhibit 5-HT 3A receptors by reducing the peak current amplitude and accelerating the rate of 5-HT-induced desensitization. However, because carboetomidate is an order of magnitude more potent an inhibitor of the 5-HT 3A receptor than is etomidate (1.9 vs 25 µM, respectively), it produces significant 5-HT 3A receptor inhibition at its hypnotic concentration of 5.4 µM.
The 5-HT 3A receptor belongs to a superfamily of homologous ligand-gated ion channels that also includes GABA A , glycine, and nicotinic acetylcholine receptors. 13 Receptors in this superfamily exist in a conformational equilibrium among resting, open, and desensitized states. [14] [15] [16] Agonist binding shifts this equilibrium, producing the changes in ion permeability that define receptor function. 14, 15, 17 In the absence of agonist, the resting state predominates. Because the ion channel in the resting state is closed, essentially no ions flow. 15 The presence of agonist shifts the receptor equilibrium toward the open state. 14 Ions flow through the open channels down their electrochemical gradients into neuronal cells, resulting in depolarization (in the case of 5-HT 3 and acetylcholine receptors) or hyperpolarization (in the case of GABA A and glycine receptors). If agonist remains bound to receptors for a prolonged time, receptors isomerize to the desensitized state in a slowly reversible process called desensitization. 15 Because the desensitized state does not allow ion flux, the desensitization process is an important negative feedback mechanism and its modulation a versatile mechanism for shaping synaptic transmission. 18 3 receptors open and close in response to agonist binding, drugs that change the rates with which receptors transition between states (i.e., their kinetics) may also produce inhibition. For example, a drug may inhibit receptor function by increasing the rates with which they isomerize to closed (resting and desensitized) states. Examples of drugs that inhibit 5-HT 3A receptors by increasing the 5-HT 3A receptor's desensitization rate include the antidepressants desipramine and imipramine. 20 The present studies with carboetomidate and etomidate indicate that these 2 hypnotics inhibit 5-HT 3A receptors by 2 similar, if not identical, mechanisms. They block open state receptors and accelerate the rates with which receptors desensitize with prolonged agonist exposure. However, the potencies of these drugs differ significantly. Carboetomidate is 5-fold more potent a blocker of peak current amplitudes and 10-fold more potent an accelerator of desensitization than is etomidate. Consequently, carboetomidate inhibits integrated currents with an IC 50 of 1.9 μM, which is an order of magnitude lower than that of etomidate and a fraction of its own hypnotic 50% effective concentration of 5.4 µM.
It is also notable that the relative potencies with which the 2 hypnotics block open state receptors and accelerate the rates with which receptors desensitize differ; compared with etomidate, carboetomidate is 13-fold more potent an accelerator of desensitization and 5-fold more potent a channel blocker. This relative potency difference suggests that these 2 receptor actions are modulated by hypnotic binding to different binding sites having different affinities for the 2 agents.
In addition to accelerating desensitization induced by prolonged (30-second) exposure to 100 µM 5-HT, we also found that carboetomidate accelerates the rate of deactivation after very brief (4-millisecond) 5-HT exposure. Interpreting this observation requires knowing what happens to receptors with brief agonist exposure. In the case of 5-HT 3A receptors, our previous studies indicate that 5-HT unbinds extremely slowly from open state receptors. 15 Consequently, many open state receptors continue to desensitize even after terminating 5-HT application because 5-HT remains bound for many seconds after the agonist has been removed from the bath solution. This important link between desensitization and deactivation explains why 5-HT 3A receptor desensitization and deactivation occur on approximately the same time scale and predicts our observation that these 2 processes are similarly affected (accelerated) by carboetomidate.
We believe that the abilities of carboetomidate and etomidate to accelerate desensitization also explain the incomplete recoveries observed in experiments using 1 µM 5-HT (Fig. 2) . Ordinarily, few receptors are desensitized in the presence of very low 5-HT concentrations because the rate with which receptors desensitize (which depends on the 5-HT concentration) is much slower than the rate with which they recover from desensitization. However, by accelerating the desensitization rate, carboetomidate and etomidate increase the fraction of receptors that are desensitized by 1 µM 5-HT and thus reduce the fraction of receptors that rapidly recover their ability to open once hypnotic is removed.
The emetogenic potential of carboetomidate is not known because mammalian studies have been limited to rats, which are unable to vomit. Nausea and vomiting are mediated by the 5-HT 3 receptor, and 5-HT 3 receptor inhibitors are frequently used for their prevention or treatment. 2, 3 With the caveat that emesis is a highly complex reflex involving multiple mechanisms, our results demonstrating that carboetomidate potently inhibits the 5-HT 3A receptor suggests that carboetomidate might be less emetogenic than etomidate in humans because it has an ondansetron-like action at hypnotic concentrations. 21, 22 Future studies using 
